clinical trial · NCT03789604
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
Non Small Cell Lung CancerCS1001 monoclonal antibodyCS1001 placebo
brief summary
This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).
started
Dec 13, 2018
primary completion
May 15, 2023
completion
Jun 30, 2027
last updated
Jul 24, 2025
official title
A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol